Nova is OVERVALUED at 81.35 per share with modest projections ahead. Nova has Sharpe Ratio of -0.0831, which conveys that the firm had -0.0831% of return per unit of risk over the last 3 months. Macroaxis standpoint towards estimating the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Nova exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to verify Nova mean deviation of 2.76, and Risk Adjusted Performance of (0.09) to check out the risk estimate we provide.